Abstract Background Bacillus Calmette-Guérin (BCG) vaccination, used against tuberculosis, is recognized for its immunomodulatory properties, a phenomenon referred to as “trained immunity.” Given these effects, there is increasing interest in evaluating its safety and impact on immune function in people living with HIV-1 (PWH). Historically, BCG was contraindicated in PWH due to safety concerns in immunocompromised individuals. This study aims to assess both the safety of BCG in PWH and its effects on the HIV-1 latent reservoir size. Methods This Phase IIA randomized, double-blind, placebo-controlled, single-center trial enrolled 60 PWH with a suppressed viral load and CD4 T-cell count 350/μl. Participants were randomized in a stepped-wedge design into equal groups for early or late BCG vaccination. Each participant received a single intradermal dose of BCG vaccine followed by a placebo three months later, or vice versa. The HIV-1 latent reservoir was quantified at three-month intervals to Day 270. The primary endpoint was the HIV-1 reservoir size six months post-vaccination, with secondary endpoints including safety outcomes. Results No significant differences were found in intact proviral HIV-1 DNA levels at six months compared to baseline. Local reactions occurred in 96% of participants, leading to scarring in 73%. No systemic infections or serious BCG-related adverse events were observed. Conclusions BCG vaccination is safe in PWH, but local skin reactions including scarring are common. There was no significant effect on the HIV-1 reservoir. These findings provide valuable insights into the safety profile of BCG vaccination in PWH, emphasizing its potential for broader immunological studies.
West et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: